A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Upadacitinib in Subjects With Giant Cell Arteritis
Phase of Trial: Phase III
Latest Information Update: 07 Dec 2019
Price : $35 *
At a glance
- Drugs Upadacitinib (Primary) ; Corticosteroid; Prednisolone
- Indications Giant cell arteritis
- Focus Registrational; Therapeutic Use
- Acronyms SELECT-GCA
- Sponsors AbbVie
- 06 Feb 2019 Planned End Date changed from 25 Apr 2023 to 14 May 2023.
- 06 Feb 2019 Status changed from not yet recruiting to recruiting.
- 05 Nov 2018 New trial record